Adolescent health briefFactors Associated With Initiation and Completion of Human Papillomavirus Vaccine Series Among Young Women Enrolled in Medicaid
Section snippets
Methods
Medicaid administrative data were obtained from the Florida Agency for Health Care Administration. The study population included all females aged 9–20 who were enrolled in the Florida Medicaid between July 2006 and June 2008 (n = 718,660). The study was approved by the University of Florida Institutional Review Board; with funding support from Merck, Inc, without any restrictions pertaining to either analyses or publication.
HPV vaccination was identified using the Current Procedural Terminology
Results
Nearly 2 years after approval by the Food and Drug administration (June 2008), 9.4% of the 11–18-year-old Medicaid-enrolled females had ever received an HPV vaccination and 1.8% had received the three-vaccine series. The majority of initial HPV vaccinations were given by pediatricians (85%), with fewer being provided by family practitioners and/or general practitioners (12%), and the least by obstetricians and/or gynecologists (1%) or internal medicine providers (1%).
As of June 2008, the
Discussion
These rates of early uptake of HPV vaccination are lower than the 25%–30% rate reported for adolescent females in other studies conducted around the same period as our study [3], [4], [7], [8], including studies on adolescents with private insurance [3]. Black females were significantly less likely as compared with either Hispanic or white females to initiate HPV vaccination or to complete the three-vaccine series, whereas Hispanic females were more likely to initiate vaccination as compared
Acknowledgments
Robert Cook conceived the study, oversaw the analysis, and wrote the manuscript; Jianyi Zhang provided data programming, data analysis, and contributed to writing; Jocelyn Mullins contributed to data analysis and writing of this manuscript; Teresa Kauf helped plan the study design, interpreted data, and edited the manuscript; Babette Brumback and Chris Mallison helped plan the study design and provided assistance with data analysis; Heather Steingraber helped plan the study design and edited
References (10)
- et al.
Understanding sexual activity defined in the HEDIS measure of screening young women for Chlamydia trachomatis
Jt Comm J Qual Improv
(2002) - et al.
Knowledge and early adoption of the HPV vaccine among girls and young women: Results of a national survey
J Adolesc Health
(2009) - et al.
Uptake of HPV vaccine: Demographics, sexual history and values, parenting style, and vaccine attitudes
J Adolesc Health
(2008) - et al.
Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR Recomm Rep
(2007) FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)
MMWR Morb Mortal Wkly Rep
(2010)
Cited by (73)
Urban-Rural Disparities in Vaccination Service Use Among Low-Income Adolescents
2021, Journal of Adolescent HealthInterventions to increase uptake of Human Papillomavirus (HPV) vaccination in minority populations: A systematic review
2020, Preventive Medicine ReportsCitation Excerpt :In 2017, 66% of adolescents aged 13–17 years started the vaccine series and 49% completed the series in the U.S., with disparities in vaccine uptake for some populations like racial and ethnic minority groups in the U.S. and other high-income countries (Van Dyne et al., 2018; Musselwhite et al., 2016; Jeudin et al., 2014). Some studies have found that Black, Hispanic, and Asian adolescents were more likely to initiate the HPV vaccine series than their white counterparts, however, were less likely to complete the series (Spencer et al., 2019; Jeudin et al., 2014; Cook et al., 2010; Widdice et al., 2011). Documented barriers to HPV vaccination of minority youth include knowledge, attitudes, and beliefs among parents, geographic location, distance to vaccination centers, immigrant or foreign-born status, acculturation levels, socioeconomic status, insurance status, and high cost of the vaccine (Ojeaga et al., 2019; Kepka et al., 2010; Tsui et al., 2013; Perkins et al. 2013; Perkins et al. 2010; Davlin et al. 2015; Bastani et al., 2011; Schluterman et al., 2011; De and Budhwani, 2017).